CVE:PAS Pascal Biosciences (PAS) Stock Price, News & Analysis → $25,000 into $109,616 in two months? (From WealthPress) (Ad) Free PAS Stock Alerts C$0.02 -0.01 (-25.00%) (As of 12/5/2022) Add Compare Share Share Today's RangeC$0.02▼C$0.0250-Day RangeC$0.02▼C$0.0252-Week RangeC$0.02▼C$0.10Volume4,000 shsAverage Volume52,289 shsMarket CapitalizationC$983,850.00P/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Pascal Biosciences alerts: Email Address Ad WealthPressThe system that called 2023’s top 7 stocks is at it again…Look 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today.Just follow this link here! About Pascal Biosciences Stock (CVE:PAS)Pascal Biosciences Inc., a biotechnology company, engages in the research and development of products for the treatment of cancer, and for the improvement of the immune system. The company's development portfolio includes PAS-403, a mitosis inhibitor that blocks cell division for the treatment of glioblastoma and brain metastases originating from other cancers; and PAS-393, an immune-stimulatory cannabinoid designed to restore the immunogenicity of tumor cells with checkpoint inhibitor therapy for use in cancer treatment. It is also developing a B-cell targeted antibody for acute lymphoblastic leukemia and B cell lymphomas; and cannabinoid therapeutic products for the treatment of COVID-19. The company has an exclusive license agreement with the University of Washington to develop a cannabinoid-based product for the treatment of glioblastoma multiforme and brain metastases; and a collaborative research agreement with SoRSE Technology Corporation to advance PAS-393 into clinical testing. Pascal Biosciences Inc. was incorporated in 2011 and is headquartered in Seattle, Washington.Read More PAS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PAS Stock News HeadlinesApril 24, 2024 | ftw.usatoday.comPascal Siakam NBA Playoff history, stats, appearances and recordApril 24, 2024 | msn.comPascal Siakam provides Pacers steadying force and voice with 37 points in Game 2 winApril 24, 2024 | Banyan Hill Publishing (Ad)The Best AI Stock to Own in the World Today is Trading for Just $25“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.April 24, 2024 | usatoday.comHow Pascal Siakam’s voice — and game —led the Pacers to evening series with BucksApril 24, 2024 | sportsbookwire.usatoday.comPascal Siakam Player Prop Bets: Pacers vs. Bucks | April 26April 24, 2024 | sports.yahoo.comPascal Siakam scores and draws the foulApril 24, 2024 | reuters.comPascal Siakam puts up 37 as Pacers pull level with BucksApril 24, 2024 | msn.comPascal Siakam leads resurgent Pacers offense in 125-108 victory that evens series with BucksApril 24, 2024 | Wealthpin Pro (Ad)One trade. One ticker. One week. Do you want to target weekly income of up to $2k or more… Starting with just $500... With just one trade per week? April 23, 2024 | forbes.comA Matt Damon And Pedro Pascal Movie Flop From 2017 Is Coming To Netflix In MayApril 22, 2024 | sportsbookwire.usatoday.comPascal Siakam Player Prop Bets: Pacers vs. Bucks | April 23April 19, 2024 | sports.yahoo.comPacers forward Pascal Siakam discusses Indiana's return to the playoffs.April 19, 2024 | msn.comColumbus Blue Jackets 2023-24 review: 3 reasons to keep coach Pascal VincentApril 19, 2024 | yahoo.com15 pics proving Sarah Paulson & Pedro Pascal are an iconic bestie duoApril 19, 2024 | sportsbookwire.usatoday.comPascal Siakam Player Prop Bets: Pacers vs. Bucks | April 21April 17, 2024 | msn.comSpider-Man 4 with Zendaya, Tom Holland gets funny Amy Pascal updateApril 16, 2024 | msn.comGladiator 2 Sounds Like It'll Continue The 25-Year Pedro Pascal Calling Card That We're Finally Getting Sick OfApril 14, 2024 | usatoday.comPascal Siakam discusses the Pacers win over Atlanta and return to the NBA Playoffs.April 14, 2024 | sportsbookwire.usatoday.comPascal Siakam Player Prop Bets: Pacers vs. Hawks | April 14April 14, 2024 | msn.comMost Fans Haven't Even Seen Footage Of Gladiator 2 Yet, And They're Already Having The Best Reactions To Paul Mescal, Pedro Pascal And Joseph QuinnApril 13, 2024 | thetimes.co.ukL&G fires warning shot at AstraZeneca over Pascal Soriot payApril 12, 2024 | msn.comPedro Almodóvar’s Queer Cowboy Movie Starring Pedro Pascal Is Now Streaming on NetflixApril 12, 2024 | msn.com‘Strange Way of Life’ on Netflix: Pedro Pascal and Ethan Hawke’s Gay Western Is Romantic AFApril 12, 2024 | sportsbookwire.usatoday.comPascal Siakam Player Prop Bets: Pacers vs. Cavaliers | April 12April 11, 2024 | theguardian.comThe danger in saying yes to Pascal Soriot’s pay rise at AstraZenecaApril 10, 2024 | thetimes.co.ukProxy advisers join Sir Pascal Soriot in the spotlightApril 10, 2024 | msn.comAmy Pascal & Kevin Feige Didn’t Know Who Zendaya Was Before Spider-Man CastingSee More Headlines Receive PAS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pascal Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeCVE SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolCVE:PAS CUSIPN/A CIKN/A Webwww.biommune.net Phone+1-604-6886775FaxN/AEmployees6Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)C($0.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-340.40% Debt Debt-to-Equity Ratio882.79 Current Ratio0.03 Quick Ratio0.17 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowC$0.00 per share Price / Cash Flow55.00 Book ValueC($0.02) per share Price / Book-0.75Miscellaneous Outstanding Shares65,590,000Free FloatN/AMarket CapC$983,850.00 OptionableNot Optionable Beta1.51 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. Harold H. Forzley C.A. (Age 69)Chief Financial Officer Comp: $16.8kDr. Brian W. Bapty Ph.D. (Age 53)CEO, Pres & Director Mr. Kevin M. Egan M.B.A.Chief Bus. OfficerKey CompetitorsiCo TherapeuticsCVE:ICOCotinga Pharmaceuticals Inc. (COT.V)CVE:COTSolarvest BioEnergyCVE:SVSBioasis TechnologiesCVE:BTIMedifocus Inc. (MFS.V)CVE:MFSView All Competitors PAS Stock Analysis - Frequently Asked Questions How have PAS shares performed in 2024? Pascal Biosciences' stock was trading at C$0.02 at the beginning of 2024. Since then, PAS shares have increased by 0.0% and is now trading at C$0.02. View the best growth stocks for 2024 here. What other stocks do shareholders of Pascal Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Pascal Biosciences investors own include Aurora Cannabis (ACB), Canadian Natural Resources (CNQ), Corus Entertainment (CJR), Auxly Cannabis Group (CBWTF), Grande West Transportation Group (BUS), Bausch Health Companies (BHC), Abattis Bioceuticals (ATT), Algonquin Power & Utilities (AQN), Aphria (APHA) and Abacus Mining & Exploration (AME). How do I buy shares of Pascal Biosciences? Shares of PAS stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. This page (CVE:PAS) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersSHOCKING Crypto Leak…Crypto 101 MediaThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsThe #1 Crypto for 2024InvestorPlaceDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pascal Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.